SELLAS Life Sciences Group, Inc.

$SLS, a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications, gapped down below its 200DMA today after it announced $20 million registered direct offering and concurrent private placement. $SLS was trading in a steep uptrend since the beginning of February before todays news.

Share This Article

 

About the Author

SELLAS Life Sciences Group, Inc.

Joey Ramson